Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study.
angiosarcoma
cardiac sarcoma
gemcitabine
sarcoma
soft tissue neoplasms
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
revised:
16
07
2022
received:
26
05
2022
accepted:
02
08
2022
pubmed:
17
8
2022
medline:
25
2
2023
entrez:
16
8
2022
Statut:
ppublish
Résumé
Gemcitabine has shown clinical activity against angiosarcoma in small series, alone, or combined with taxanes. We aimed to evaluate its activity as a single-agent in a larger series of patients with advanced angiosarcoma. We retrospectively reviewed the electronic medical records of consecutive adult patients with advanced angiosarcoma treated with single-agent gemcitabine at our institutions from January 2010 to January 2021. Response was evaluated according to RECIST 1.1, and toxicity was graded according to NCI-CTC v5.0. 42 patients were identified. 38 patients (90%) had received prior anthracyclines and weekly paclitaxel, and 9 (21%) had received pazopanib. The best tumor response was partial response (PR) in 16 patients (38%), or stable disease (10 patients, 24%). All 8 patients with cardiac angiosarcoma experienced a PR. Median PFS was 5.4 months (95%CI: 3.1-6.5), and median OS was 9.9 months (95%CI: 6.6-13.4). Single-agent gemcitabine has clinically meaningful activity in advanced, heavily pre-treated angiosarcoma.
Identifiants
pubmed: 35971325
doi: 10.1002/cam4.5147
pmc: PMC9939156
doi:
Substances chimiques
Gemcitabine
0
Deoxycytidine
0W860991D6
Taxoids
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3160-3166Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Chen TW, Burns J, Jones RL, Huang PH. Optimal clinical management and the molecular biology of angiosarcomas. Cancers (Basel). 2020;12(11):3321. doi:10.3390/cancers12113321
Penel N, Italiano A, Ray-Coquard I, et al. French sarcoma group (GSF/GETO). Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol. 2012;23(2):517-523. doi:10.1093/annonc/mdr138
Lund B, Kristjansen PE, Hansen HH. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev. 1993;19(1):45-55. doi:10.1016/0305-7372(93)90026-n
Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Phase II trial of gemcitabine in advanced sarcomas. Cancer. 2002;94(12):3225-3229. doi:10.1002/cncr.10602
Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study. Cancer Chemother Pharmacol. 2000;45(2):177-181. doi:10.1007/s002800050027
Ducoulombier A, Cousin S, Kotecki N, Penel N. Gemcitabine-based chemotherapy in sarcomas: a systematic review of published trials. Crit Rev Oncol Hematol. 2016;98:73-80. doi:10.1016/j.critrevonc.2015.10.020
Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001;19(15):3483-3489. doi:10.1200/JCO.2001.19.15.3483
Kajihara I, Maeda S, Yamada S, et al. Biweekly gemcitabine therapy induces complete remission in cutaneous angiosarcoma resistant to multiple anticancer drugs. J Dermatol. 2015;42(12):1197-1198. doi:10.1111/1346-8138.13077
Yonezawa I, Waki M, Tamura Y, et al. Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification. Curr Oncol. 2014;21(6):e782-e789. doi:10.3747/co.21.2144
Luo ZG, Wang Q, Peng W, Hu XC, Hong XN. Advanced breast angiosarcoma completely responding to gemcitabine-containing chemotherapy. Breast Care (Basel). 2012;7(5):414-416. doi:10.1159/000343614
Tsubouchi K, Yoshioka H, Ishida T. Significant response to gemcitabine monotherapy in primary pleural epithelioid angiosarcoma. J Thorac Oncol. 2012;7(5):942-943. doi:10.1097/JTO.0b013e31824feab8
Bender L, Gantzer J, Somme F, Weingertner N, Kurtz JE. Complete response of a pleural, hepatic, and splenic metastatic primary breast angiosarcoma using gemcitabine monotherapy. JCO Oncol Pract. 2020;16(4):181-183. doi:10.1200/JOP.19.00609
Stacchiotti S, Palassini E, Sanfilippo R, et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian rare cancer network. Ann Oncol. 2012;23(2):501-508. doi:10.1093/annonc/mdr066
Gronchi A, Miah AB, Dei Tos AP, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021 Nov;32:1348-1365. doi:10.1016/j.annonc.2021.07.006
Vergier B, Cany L, Bonnet F, Robert J, de Mascarel A, Coindre JM. Expression of MDR1/P glycoprotein in human sarcomas. Br J Cancer. 1993;68(6):1221-1226. doi:10.1038/bjc.1993.508
Bergman AM, Pinedo HM, Talianidis I, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer. 2003;88(12):1963-1970. doi:10.1038/sj.bjc.6601011
Lum BL, Gosland MP, Kaubisch S, Sikic BI. Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy. 1993;13(2):88-109.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247. doi:10.1016/j.ejca.2008.10.026 https://ctep.cancer.gov/, last accessed on March 18th, 2022
Altman DG, Bland JM. Time to event (survival) data. BMJ. 1998;317(7156):468-469. doi:10.1136/bmj.317.7156.468
Kollár A, Jones RL, Stacchiotti S, et al. Pazopanib in advanced vascular sarcomas: an EORTC soft tissue and bone sarcoma group (STBSG) retrospective analysis. Acta Oncol. 2017;56(1):88-92. doi:10.1080/0284186X.2016.1234068
Mir O, Domont J, Cioffi A, et al. Feasibility of metronomic oral cyclophosphamide plus prednisolone in elderly patients with inoperable or metastatic soft tissue sarcoma. Eur J Cancer. 2011;47(4):515-519. doi:10.1016/j.ejca.2010.11.025
Painter CA, Jain E, Tomson BN, et al. The angiosarcoma project: enabling genomic and clinical discoveries in a rare cancer through patient- partnered research. Nat Med. 2020;26(2):181-187. doi:10.1038/s41591-019-0749-z
Ray-Coquard I, Italiano A, Bompas E, et al. French sarcoma group (GSF/GETO). Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French sarcoma group (GSF/GETO). Oncologist. 2012;17(2):260-266. doi:10.1634/theoncologist.2011-0237
Agulnik M, Schulte B, Robinson S, et al. An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma. Eur J Cancer. 2021;154:201-208. doi:10.1016/j.ejca.2021.06.027
Ray-Coquard IL, Domont J, Tresch-Bruneel E, et al. Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial. J Clin Oncol. 2015;33(25):2797-2802. doi:10.1200/JCO.2015.60.8505
Mir O, Watson S, Massard C, Le Cesne A, Benhadji KA, Soria JC. Sequential treatment with NOTCH inhibitor crenigacestat followed by pazopanib in soft tissue sarcoma patients. Ann Oncol. 2020;31(12):1782-1784. doi:10.1016/j.annonc.2020.09.003
Florou V, Rosenberg AE, Wieder E, et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer. 2019;7(1):213. doi:10.1186/s40425-019-0689-7
Petitprez F, de Reyniès A, Keung EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature. 2020;577(7791):556-560. doi:10.1038/s41586-019-1906-8
Fujisawa Y, Fujimura T, Matsushita S, et al. The efficacy of eribulin mesylate for patients with cutaneous angiosarcoma previously treated with taxane: a multicentre prospective observational study. Br J Dermatol. 2020;183(5):831-839. doi:10.1111/bjd.19042
Patel SD, Peterson A, Bartczak A, et al. Primary cardiac angiosarcoma - a review. Med Sci Monit. 2014;20:103-109. doi:10.12659/MSM.889875
Maréchal R, Bachet JB, Mackey JR, et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology. 2012;143(3):664-674.e6. doi:10.1053/j.gastro.2012.06.006
Vincenzi B, Stacchiotti S, Collini P, et al. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. Br J Cancer. 2017;117(3):340-346. doi:10.1038/bjc.2017.187